Phase Ib study of a high potent PI3K-mTOR dual inhibitor WX390 combined with toripalimab in patients with advanced solid tumors

被引：0
|
作者：
Zhang, Songling
Zhu, Xiaoxue
Gao, Lei
Qi, Yaling
Jia, Xiao
Li, Yongguo
Guo, Ye
Ding, Yanhua
机构：
[1] First Hosp Jilin Univ, Gynecol & Obstet Ctr, Dept Gynecol Oncol, Changchun, Peoples R China
[2] First Hosp Jilin Univ, Phase Clin Res Ctr 1, Changchun, Peoples R China
[3] First Hosp Jilin Univ, Changchun, Peoples R China
[4] Shanghai Jiatan Pharmatech CO LTD, Shanghai, Peoples R China
[5] Tongji Univ, Shanghai East Hosp, Shanghai, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e14627
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Phase I Study of the Pan-PI3K Inhibitor Buparlisib in Adult Chinese Patients with Advanced Solid Tumors
    Wu, Yi-Long
    Zhang, Li
    Trandafir, Lucia
    Dong, Tuochuan
    Duval, Vincent
    Hazell, Katharine
    Xu, Binghe
    ANTICANCER RESEARCH, 2016, 36 (11) : 6185 - 6194
  • [32] A Phase I study of intravenous PI3K inhibitor copanlisib in Japanese patients with advanced or refractory solid tumors
    Toshihiko Doi
    Nozomu Fuse
    Takayuki Yoshino
    Takashi Kojima
    Hideaki Bando
    Hideaki Miyamoto
    Masato Kaneko
    Motonobu Osada
    Atsushi Ohtsu
    Cancer Chemotherapy and Pharmacology, 2017, 79 : 89 - 98
  • [33] A phase 1 study of selective PI3K. inhibitor ZX-4081 in patients with advanced solid tumors
    Qin, Xiaoli
    Bautista, Edgar
    Li, Ying-ying
    Li, Xiaomin
    Peng, Zhiyuan
    Kong, Deming
    Yang, Jinfu
    Hao, Xiaolin
    CANCER RESEARCH, 2022, 82 (12)
  • [34] A Phase I study of intravenous PI3K inhibitor copanlisib in Japanese patients with advanced or refractory solid tumors
    Doi, Toshihiko
    Fuse, Nozomu
    Yoshino, Takayuki
    Kojima, Takashi
    Bando, Hideaki
    Miyamoto, Hideaki
    Kaneko, Masato
    Osada, Motonobu
    Ohtsu, Atsushi
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2017, 79 (01) : 89 - 98
  • [35] Phase 1/1b dose escalation and expansion study of BEZ235, a dual PI3K/mTOR inhibitor, in patients with advanced solid tumors including patients with advanced breast cancer
    Rodon, Jordi
    Perez-Fidalgo, Alejandro
    Krop, Ian E.
    Burris, Howard
    Guerrero-Zotano, Angel
    Britten, Carolyn D.
    Becerra, Carlos
    Schellens, Jan
    Richards, Donald A.
    Schuler, Martin
    Abu-Khalaf, Maysa
    Johnson, Faye M.
    Ranson, Malcolm
    Edenfield, Jeff
    Silva, Antonio P.
    Hackl, Wolfgang
    Quadt, Cornelia
    Demanse, David
    Duval, Vincent
    Baselga, Jose
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2018, 82 (02) : 285 - 298
  • [36] Phase 1/1b dose escalation and expansion study of BEZ235, a dual PI3K/mTOR inhibitor, in patients with advanced solid tumors including patients with advanced breast cancer
    Jordi Rodon
    Alejandro Pérez-Fidalgo
    Ian E. Krop
    Howard Burris
    Angel Guerrero-Zotano
    Carolyn D. Britten
    Carlos Becerra
    Jan Schellens
    Donald A. Richards
    Martin Schuler
    Maysa Abu-Khalaf
    Faye M. Johnson
    Malcolm Ranson
    Jeff Edenfield
    Antonio P. Silva
    Wolfgang Hackl
    Cornelia Quadt
    David Demanse
    Vincent Duval
    Jose Baselga
    Cancer Chemotherapy and Pharmacology, 2018, 82 : 285 - 298
  • [37] A phase Ib study of prexasertib, a checkpoint kinase (CHK1) inhibitor, and LY3023414, a dual inhibitor of class I phosphatidylinositol 3-kinase (PI3K) and the mammalian target of rapamycin (mTOR) in patients with advanced solid tumors.
    Hong, David S.
    Moore, Kathleen N.
    Bendell, Johanna C.
    Karp, Daniel D.
    Wang, Judy Sing-Zan
    Ulahannan, Susanna Varkey
    Johnson, Melissa Lynne
    Aljumaily, Raid
    Hynes, Scott
    Callies, Sophie
    Decker, Rodney
    LaBell, Elizabeth
    Niland, Michele
    Wang, Xuejing Aimee
    Lin, Aimee Bence
    Patel, Manish R.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [38] Phase I Dose-escalation Study of the Oral Dual MTOR/PI3K Inhibitor BEZ235, Solid Dispersion System (SDS) Sachet Formulation, in Patients with Advanced Solid Tumors
    Rodon Ahnert, J.
    Burris, H. A.
    Schellens, J. H. M.
    Schuler, M.
    Goodman, O.
    Britten, C.
    Richards, D.
    Demanse, D.
    Silva, A.
    Baselga, J.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : 112 - 112
  • [39] A Phase Ib study of Wee1 inhibitor adavosertib in patients with advanced solid tumors
    Falchook, Gerald S.
    Sachdev, Jasgit
    Imedio, Esteban Rodrigo
    Kumar, Sanjeev
    Mugundu, Ganesh
    Chmielecki, Juliann
    Jones, Suzanne
    Spigel, David R.
    Johnson, Melissa
    CANCER RESEARCH, 2019, 79 (13)
  • [40] Correction to: Phase Ib Trial of the PI3K Inhibitor Copanlisib Combined with the Allosteric MEK Inhibitor Refametinib in Patients with Advanced Cancer
    Ramesh K. Ramanathan
    Daniel D. Von Hoff
    Ferry Eskens
    George Blumenschein
    Donald Richards
    Isabelle Genvresse
    Susanne Reschke
    Camille Granvil
    Adam Skubala
    Carol Peña
    Klaus Mross
    Targeted Oncology, 2020, 15 : 803 - 803
12345